Aidigong Maternal & Child Health Limited disclosed on 27 May 2026 that Hong Kong Exchanges and Clearing Limited (HKEX) has issued additional resumption guidance after the company fell out of compliance with several Listing Rules following the 20 May resignation of independent non-executive director (INED) Wang Bin.

The HKEX letter dated 22 May 2026 requires Aidigong to re-establish compliance with Rules 3.10(1), 3.10A, 3.21, 3.25, 3.27A and 13.92(2). Specifically, the board must: • Restore the minimum number of INEDs and adjust the ratio between INEDs and executive directors; • Reconstitute the audit committee to meet statutory composition thresholds; • Re-establish remuneration and nomination committees that are chaired by an INED (or the board chairman for the nomination committee) and comprise a majority of INEDs.

The additional directives supplement the initial resumption guidance issued on 12 March 2025. Aidigong’s board now consists of two executive directors—Huang Wenhua and Li Runping—and one INED, Ma Siu Kit, leaving multiple committee roles unfilled.

Trading in Aidigong shares has been suspended since 21 February 2025 at 9:54 a.m. and will remain halted until the HKEX confirms full compliance with the resumption guidance. The company stated it will provide further updates as progress is made.

Shareholders and potential investors are advised to exercise caution when dealing in Aidigong securities.